{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:06Z","timestamp":1793813946060,"version":"4.6.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071494 81871043"],"award-info":[{"award-number":["82071494 81871043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0028 2021YFS0145"],"award-info":[{"award-number":["2022YFS0028 2021YFS0145"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Tumor necrosis factor alpha inhibitors (TNFi) have shown substantial efficacy in alleviating and treating ankylosing spondylitis (AS). However, the heightened interest is accompanied by concerns over adverse events. In this meta-analysis, we analyzed both serious and common adverse events in patients treated with tumor necrosis factor alpha inhibitors compared with those in the placebo group.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We searched for clinical trials in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data, and VIP Data. Studies were selected based on strict inclusion and exclusion criteria. Only randomized, placebo-controlled trials were included in the final analysis. RevMan 5.4 software was used for performing meta-analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 18 randomized controlled trials recruiting 3,564 patients with ankylosing spondylitis were included, with overall moderate to high methodological quality. Compared with the placebo group, the incidences showed no difference and were only slightly increased numerically for serious adverse events, serious infections, upper respiratory tract infection, and malignancies in patients treated with tumor necrosis factor alpha inhibitors. However, tumor necrosis factor alpha inhibitor treatment significantly increased the incidence of overall adverse events, nasopharyngitis, headache, and injection-site reactions in ankylosing spondylitis patients when compared with placebo.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The available data indicated that ankylosing spondylitis patients who received tumor necrosis factor alpha inhibitors had no significantly increased risks of serious adverse events when compared with the placebo group. However, tumor necrosis factor alpha inhibitors significantly increased the incidence rate of common adverse events, including nasopharyngitis, headache, and injection-site reactions. Large-scale and long-term follow-up clinical trials are still necessary to further investigate the safety of tumor necrosis factor alpha inhibitors in ankylosing spondylitis treatment.<\/jats:p>","DOI":"10.3389\/fphar.2023.1084614","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T07:48:57Z","timestamp":1676274537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Haihuan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e12693","DOI":"10.1111\/dth.12693","article-title":"Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature","volume":"31","author":"Babuna Kobaner","year":"2018","journal-title":"Dermatol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatol. Oxf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatol. (United Kingdom)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/RHU.0000000000001853","article-title":"Efficacy and safety of intravenous golimumab in ankylosing spondylitis patients with early and late disease through one year of the GO-ALIVE study","volume":"28","author":"Deodhar","year":"2022","journal-title":"J. Clin. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: Results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","article-title":"Risk of infection associated with anti-TNF-\u03b1 therapy","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: A systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1479-5876-12-77","article-title":"Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-\u03b1 antagonists","volume":"12","author":"Germano","year":"2014","journal-title":"J. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-017-8623-6","article-title":"The comparative safety of TNF inhibitors in ankylosing spondylitis-a meta-analysis update of 14 randomized controlled trials","volume":"54","author":"Hou","year":"2018","journal-title":"Clin. Rev. Allergy. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: Results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B18","first-page":"741","article-title":"A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis","volume":"49","author":"Huang","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B19","first-page":"1043","article-title":"A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis","volume":"50","author":"Huang","year":"2011","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J. Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2203\/dose-response.09-056.Kraig","article-title":"TNF-\u0391 and microglial hormetic involvement in neurological health & migraine","volume":"8","author":"Kraig","year":"2010","journal-title":"Dose Response"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"32768","DOI":"10.1038\/srep32768","article-title":"Efficacy and safety of TNF-\u03b1 inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3760\/cma.j.issn.0578-1426.2017.12.009","article-title":"The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis","volume":"56","author":"Ma","year":"2017","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e7145","DOI":"10.1097\/MD.0000000000007145","article-title":"Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis","volume":"96","author":"Ma","year":"2017","journal-title":"Med. Baltim."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: A meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: A meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4161\/bbug.1.4.12105","article-title":"Biologic TNF\u03b1-inhibitors that cross the human blood-brain barrier","volume":"1","author":"Pardridge","year":"2010","journal-title":"Bioeng. Bugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ddr.21285","article-title":"Safety of anti-TNF therapies in immune-mediated inflammatory diseases: Focus on infections and malignancy","volume":"76","author":"Pereira","year":"2015","journal-title":"Drug Dev. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/01.wnl.0000101717.16799.8f","article-title":"Association between the tumor necrosis factor-alpha -308 G\/A gene polymorphism and migraine","volume":"62","author":"Rainero","year":"2014","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","author":"Raychaudhuri","year":"2014","journal-title":"J. Autoimmun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","article-title":"Epidemiology of spondyloarthritis in North America","volume":"341","author":"Reveille","year":"2011","journal-title":"Am. J. Med. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1526-4610.2006.00722.x","article-title":"Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine","volume":"47","author":"Rozen","year":"2007","journal-title":"Headache"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1038\/s41467-021-26750-6","article-title":"Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis","volume":"12","author":"Shao","year":"2021","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e12817","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17a antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"","journal-title":"Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","article-title":"The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: Are TNF inhibitors safer than we thought?","volume":"59","author":"Wro\u0144ski","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.12998\/wjcc.v8.i7.1213","article-title":"Clinical significance and prognostic value of tumor necrosis factor-\u03b1 and dickkopf related protein-1 in ankylosing spondylitis","volume":"8","author":"Xiong","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3892\/etm.2017.5003","article-title":"Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials","volume":"14","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00296-020-04537-0","article-title":"Prevalence of ankylosing spondylitis in a Chinese population: A systematic review and meta-analysis","volume":"40","author":"Zhao","year":"2020","journal-title":"Rheumatol. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: Etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1084614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T19:35:19Z","timestamp":1676403319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1084614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":47,"alternative-id":["10.3389\/fphar.2023.1084614"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1084614","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1084614"}}